Home › Trial NCT03278717
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients
- Trial IDNCT03278717
- StatusUnknown
- PhasePhase 3
- Study typeInterventional
- SponsorUniversity College, London
- Enrollment330
- Start date2018-06-15
- ConditionsOvarian Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.